Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 October 2023Website:
http://nkgenbiotech.comNext earnings report:
31 December 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 23 min agoDividend
Analysts recommendations
Institutional Ownership
NKGN Latest News
Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2 levels, which are detectable up to 10 years before dementia symptoms appear according to recent reports. This suggests a potential role for the use of troculeucel in delaying or preventing dementia onset in asymptomatic individuals with detectable biomarkers.
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive scores, resulting in a clinical upgrade from moderate AD to mild AD after only three months on therapy.
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the cerebral spinal fluid (CSF) of Alzheimer's patients; an important finding since increased α-syn has been correlated with worse cognitive performance and is not a target for any currently approved Alzheimer's treatments
SANTA ANA, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that it will present new biomarker data on SNK01 (autologous non-genetically modified NK cell therapy) in Alzheimer's disease during a poster presentation at the upcoming Alzheimer's Association International Conference (“AAIC”) to be held in Philadelphia, PA at the Pennsylvania Convention Center and online from July 28 – August 1, 2024.
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024.
SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.
SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.
NKGen Biotech (NASDAQ: NKGN ) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2 clinical trial. The company says that its Safety Review Committee has given it the go-ahead to start its Phase 2 clinical study of SNK01.
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a biotechnology company in the clinical stage, focusing on developing and selling innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, has announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will be presenting key features of the Company's cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01. This product has shown increased cytotoxicity and activating receptor expression for treating neurodegenerative diseases and solid tumors. The presentation will take place at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) in Nanjing, China, from May 22–24, 2024.
What type of business is NKGen Biotech Common Stock?
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
What sector is NKGen Biotech Common Stock in?
NKGen Biotech Common Stock is in the Healthcare sector
What industry is NKGen Biotech Common Stock in?
NKGen Biotech Common Stock is in the Biotechnology industry
What country is NKGen Biotech Common Stock from?
NKGen Biotech Common Stock is headquartered in United States
When did NKGen Biotech Common Stock go public?
NKGen Biotech Common Stock initial public offering (IPO) was on 02 October 2023
What is NKGen Biotech Common Stock website?
https://nkgenbiotech.com
Is NKGen Biotech Common Stock in the S&P 500?
No, NKGen Biotech Common Stock is not included in the S&P 500 index
Is NKGen Biotech Common Stock in the NASDAQ 100?
No, NKGen Biotech Common Stock is not included in the NASDAQ 100 index
Is NKGen Biotech Common Stock in the Dow Jones?
No, NKGen Biotech Common Stock is not included in the Dow Jones index
When was NKGen Biotech Common Stock the previous earnings report?
No data
When does NKGen Biotech Common Stock earnings report?
The next expected earnings date for NKGen Biotech Common Stock is 31 December 2024